Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

0.4046 -0.0193 (-4.55%)
Streaming Delayed Price Updated: 11:16 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Which stocks are most active on Monday? ↗
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Group Plc (NASDAQ:MREO) Beats Q3 2025 EPS Estimates, Maintains Cash Runway into 2027 ↗
Mereo BioPharma (MREO) beat Q3 EPS estimates with a narrower loss. The clinical-stage company has cash into 2027 and key data for its lead drug expected soon. 
Via Chartmill
News headline image
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks ↗
HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Thursday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
US Stocks Mixed; Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease ↗
The study will continue onto a third and final analysis toward the end of the year. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.